Type 1 diabetes mellitus (T1DM) is a complex autoimmune disease characterized by the immune-mediated destruction of pancreatic beta cells resulting in complete and irreversible loss of endogenous insulin production. Although it can occur at any age, T1DM primarily affects children and adolescents. Its global incidence has been rising steadily, with a disproportionately sharp increase observed in low- and middle-income countries (LMICs). The epidemiological patterns of T1DM demonstrate significant variability, influenced by age, ethnicity, and geographical region. The pathogenesis of T1DM reflects a complex interaction between genetic predisposition, particularly within the HLA region, and environmental modulators such as viral agents, early dietary exposures, and gut microbiome alterations. The disease progresses through predictable stages, from asymptomatic autoimmunity to overt hyperglycemia, often presenting initially with acute metabolic complications like diabetic ketoacidosis (DKA). Diagnosis is based on recognition of classical symptoms and biochemical confirmation of hyperglycemia, supported by the detection of pancreatic islet autoantibodies. Measurement of C-peptide levels may help in distinguishing T1DM from other diabetes subtypes. Effective management requires a comprehensive, multidisciplinary approach involving intensive insulin therapy, glucose monitoring, individualized medical nutritional therapy, structured physical activity, and sustained psychosocial support for both patients and their families. Advances in diabetes technologies, including continuous glucose monitoring systems (CGM), insulin pump therapy, automated insulin delivery systems (AID), smart insulin pens, and mobile health applications, have significantly improved glycemic control and overall quality of life. Emerging disease-modifying immunotherapies and pancreatic replacement strategies represent promising horizons aimed at preserving endogenous insulin production and potentially altering disease progression.